Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MASS 
908 Devices Inc (MASS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MASS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -34% | Avg. Invested days 17 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 225.90M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 4 | Beta 0.37 | 52 Weeks Range 1.81 - 8.06 | Updated Date 08/29/2025 |
52 Weeks Range 1.81 - 8.06 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.36 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.17 | Actual -0.37 |
Profitability
Profit Margin -28.13% | Operating Margin (TTM) -64.2% |
Management Effectiveness
Return on Assets (TTM) -15.39% | Return on Equity (TTM) -53.4% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 111743469 | Price to Sales(TTM) 3.45 |
Enterprise Value 111743469 | Price to Sales(TTM) 3.45 | ||
Enterprise Value to Revenue 1.7 | Enterprise Value to EBITDA -3.15 | Shares Outstanding 36085700 | Shares Floating 22134967 |
Shares Outstanding 36085700 | Shares Floating 22134967 | ||
Percent Insiders 8.37 | Percent Institutions 83.29 |
Upturn AI SWOT
908 Devices Inc
Company Overview
History and Background
908 Devices Inc. was founded in 2012. It focuses on developing handheld and desktop mass spectrometry devices for chemical and biomolecular analysis. The company went public in December 2020.
Core Business Areas
- Handheld Products: Develops and sells handheld mass spectrometry devices for rapid chemical analysis in the field.
- Desktop Products: Offers compact desktop mass spectrometry devices for laboratory-based analysis.
- Consumables and Services: Provides consumables, software, and support services for its instruments.
Leadership and Structure
Dr. Kevin J. Knopp is the CEO. The company has a typical corporate structure with departments for R&D, sales, marketing, operations, and finance.
Top Products and Market Share
Key Offerings
- MX908: A handheld high-pressure mass spectrometer used for chemical threat detection, hazmat response, and drug interdiction. Competitors include Smiths Detection and FLIR Systems. Revenue details by product are not publicly disaggregated.
- Rebel: A desktop bioreactor sampling system for real-time monitoring of cell culture and fermentation processes. Competitors include Thermo Fisher Scientific and Agilent Technologies. Revenue details by product are not publicly disaggregated.
Market Dynamics
Industry Overview
The mass spectrometry market is growing, driven by increasing demand for rapid and accurate chemical analysis in various fields, including security, pharmaceuticals, and bioprocessing.
Positioning
908 Devices Inc. is positioned as an innovator in portable and compact mass spectrometry. Its competitive advantages include speed, portability, and ease of use.
Total Addressable Market (TAM)
Estimated TAM in the billions of USD. 908 Devices addresses several segments like bioprocessing, forensics and industrial, and is positioned to grow with expansion of its product lines
Upturn SWOT Analysis
Strengths
- Innovative technology
- Portable and compact devices
- Strong application focus
- Established customer base
Weaknesses
- Limited scale compared to larger competitors
- Reliance on single-source suppliers
- Relatively high product prices
- Negative Profitability
Opportunities
- Expanding into new applications
- Increasing adoption of portable mass spectrometry
- Strategic partnerships
- Growing demand in bioprocessing
Threats
- Competition from established players
- Technological advancements by competitors
- Economic downturns affecting capital spending
- Regulatory changes
Competitors and Market Share
Key Competitors
- WAT
- SCI
- KEYS
Competitive Landscape
908 Devices competes with larger, established players in the mass spectrometry market. Its competitive advantage lies in its portable and compact devices, but it faces challenges in terms of scale and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Historical revenue growth has been strong, driven by product adoption and market expansion.
Future Projections: Analysts project continued revenue growth, but profitability remains a key challenge.
Recent Initiatives: Focus on expanding product offerings, increasing sales and marketing efforts, and improving operational efficiency.
Summary
908 Devices is an innovative company in the mass spectrometry space, known for its portable and compact devices. While revenue growth has been strong, the company is still not profitable and faces competition from larger players. Continued innovation and expansion into new markets are crucial for its future success. Profitability is something to look out for.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Company Website
- Market Research Reports
Disclaimers:
The data provided is for informational purposes only and should not be considered financial advice. Market share figures are estimates and may not be precise. The AI-based rating is generated algorithmically and should be used as one factor among many in investment decision-making. Financial figures are rounded.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 908 Devices Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2020-12-18 | Co-Founder, CEO, President & Director Dr. Kevin J. Knopp Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 246 | Website https://908devices.com |
Full time employees 246 | Website https://908devices.com | ||
908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices for use in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. Its products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as process fingerprint data to support large-scale efforts in predictive bioprocess modeling. The company's products comprise Maven, an on-line device for bioprocess monitoring and control; Trace C2, an on-line monitoring of methanol or ethanol and control of substrate feeding in fermentation processes; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.